Congenital nephrotic syndrome type 2, or NPHS2-associated nephrotic syndrome, is a hereditary podocytopathy that can manifest from the first few months of life to adulthood. It is due to biallelic pathogenic variants in NPHS2 and follows an autosomal recessive pattern. Alteration of podocin weakens the glomerular barrier and causes intense protein loss in the urine, usually resistant to corticosteroids.
Congenital nephrotic syndrome type 2
NPHS2 encodes podocin, a membrane protein mainly expressed in the podocytes of the renal glomerulus. It is located in the slit diaphragm, situated between the extensions of these cells, and contributes to preventing the passage of plasma proteins into the urinary filtrate. Podocin organizes complexes with nephrin and maintains podocyte cytoskeleton signaling and stability.
Pathogenic variants can prevent podocin from reaching the membrane, alter its oligomerization, or destabilize the slit diaphragm. As a consequence, foot process effacement, persistent proteinuria, and often, focal segmental glomerulosclerosis occur. The exact prevalence is unknown; NPHS2 is one of the most frequent monogenic causes of steroid-resistant nephrotic syndrome. The spectrum varies among populations, and founder effects have been described, such as that associated with p.Arg138Gln in Europe.
Symptoms
The presentation includes heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. Onset usually occurs in childhood, although congenital, juvenile, and adult forms exist. Early cases may present with generalized edema, growth retardation, infections, thyroid disorders, or thrombosis due to urinary protein loss. The disease is usually resistant to glucocorticoids and can progress to chronic kidney disease and renal failure. Genotypes with severe functional loss tend to present earlier, while some hypomorphic alleles are associated with late onset and slower progression.
Disease management
Currently, there is no curative treatment that restores podocin function. Management includes nephrological follow-up and control of proteinuria, blood pressure, renal function, growth, and metabolic or thrombotic complications. Renin-angiotensin-aldosterone system inhibitors can reduce proteinuria; diuretics, albumin, and other measures are used according to the clinical situation. After confirming a genetic cause, prolonged immunosuppressive treatments without benefit should be avoided. In case of renal failure, dialysis or transplantation is used, with a very low risk of recurrence in NPHS2. Strategies to correct mutant podocin folding and trafficking remain in the preclinical phase.
Genes analyzed
Bibliography
Lipska-Ziętkiewicz BS. Genetic Steroid-Resistant Nephrotic Syndrome Overview. GeneReviews®. 2021.
Mertens ND, Nicolas Frank C, Bolsius L, et al. NPHS2 Revisited Through 208 Cases and Podocin Complex Modeling. Kidney Int Rep. 2026;11(5):106366.
Trautmann A, Vivarelli M, Samuel S, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol. 2020;35(8):1529-1561.
